Hextwo Capital

Hextwo Capital is an investment company focused on the life sciences and biotechnology sector, specializing in RNA therapeutics and other advanced biotechnologies. The firm actively participates in venture capital funding rounds, strategically targeting innovative companies developing cutting-edge treatments and platforms. Hextwo Capital notably served as an investor in CamGene Therapeutics' oversubscribed seed funding round, which concluded in October 2025, supporting their pioneering work on RNA-based treatments for hearing loss. The organization benefits from the scientific leadership of its co-founder, Professor Pieter Cullis, a globally recognized authority in the lipid nanoparticle (LNP) space, whose expertise informs its investment thesis. This strategic alignment with scientific pioneers positions Hextwo Capital to identify and support promising early-stage ventures within the rapidly evolving biotechnology landscape, driving innovation in critical health areas.